Important Information
If you are interested in applying for this study, please:
- read the study description.
- review the Visit Planner dates in your location and confirm that you are available for the stated dates.
- If you have not yet registered with us, click on the ‘Register’ button at the top of this page and answer the questions.
- If you have already registered with us, answer the pre-screening questions listed below and submit your interest.
We will then contact you to check your suitability and share the Participant Informed Consent Form for you to read.
Study Information
New Zealand Clinical Research is trialling an investigational medicine that could help people with lung conditions such as asthma and chronic obstructive pulmonary disease (COPD).
People with asthma or COPD often have difficulty breathing due to blocked airways, coughing, and chest tightness. These symptoms are mainly caused by inflammation in the airways.
The investigational medicine, QX031N, is being developed to treat these lung conditions by targeting proteins that drive inflammation in the airways. By blocking these proteins, QX031N may help reduce inflammation in the airways, making it easier to breathe and relieving the symptoms of asthma and COPD.
This is an investigational drug because it has not been approved by MedSafe or other drug regulatory authorities.
This study (2025 FULL 24407) is being funded by Qyuns Therapeutics Co., Ltd and has been approved by the Health and Disability Ethics Committee.
Requirements
Healthy Males and Females
- Aged between 18 – 65 years
- BMI (Body Mass Index) between 18 – 32 kg/m²
- Smokers/Vapers allowed
- Not currently taking any regular prescription medications or supplements
- No history of tuberculosis (TB)
What is Involved?
Study Visits: 4-night stay + 2 x 3-night stay + 12 clinic visit
Payment: $11,000 before tax